These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 12656132

  • 1. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
    Edmond LM, Hopkins MJ, Magee EA, Cummings JH.
    Inflamm Bowel Dis; 2003 Jan; 9(1):10-7. PubMed ID: 12656132
    [Abstract] [Full Text] [Related]

  • 2. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
    Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB.
    Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
    [Abstract] [Full Text] [Related]

  • 3. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE, Kane S.
    Rev Gastroenterol Disord; 2004 Mar; 4(2):86-91. PubMed ID: 15185719
    [Abstract] [Full Text] [Related]

  • 4. Balsalazide.
    Prakash A, Spencer CM.
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [Abstract] [Full Text] [Related]

  • 5. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD.
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [Abstract] [Full Text] [Related]

  • 6. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC.
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [Abstract] [Full Text] [Related]

  • 7. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K, Williams JG.
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
    [Abstract] [Full Text] [Related]

  • 8. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
    Simmonds NJ, Millar AD, Blake DR, Rampton DS.
    Aliment Pharmacol Ther; 1999 Mar; 13(3):363-72. PubMed ID: 10102970
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
    Kane SV, Bjorkman DJ.
    Rev Gastroenterol Disord; 2003 Mar; 3(4):210-8. PubMed ID: 14668693
    [Abstract] [Full Text] [Related]

  • 10. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I, Kawasaki M, Nagahama S, Matsuda A, Kataoka M, Kokuba Y.
    Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
    [Abstract] [Full Text] [Related]

  • 11. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK.
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [Abstract] [Full Text] [Related]

  • 12. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV, Kane SV, Bjorkman D.
    Aliment Pharmacol Ther; 2004 Jan 15; 19(2):179-89. PubMed ID: 14723609
    [Abstract] [Full Text] [Related]

  • 13. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH, Munck LK.
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar 15; 4(3):160-70. PubMed ID: 17339853
    [Abstract] [Full Text] [Related]

  • 14. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
    Dhaneshwar SS.
    World J Gastroenterol; 2014 Apr 07; 20(13):3564-71. PubMed ID: 24707139
    [Abstract] [Full Text] [Related]

  • 15. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Apr 07; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 16. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB, Goa KL.
    Drugs; 2002 Apr 07; 62(11):1689-705. PubMed ID: 12109930
    [Abstract] [Full Text] [Related]

  • 17. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
    Nikfar S, Rahimi R, Rezaie A, Abdollahi M.
    Dig Dis Sci; 2009 Jun 07; 54(6):1157-70. PubMed ID: 18770034
    [Abstract] [Full Text] [Related]

  • 18. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Baker DE.
    Rev Gastroenterol Disord; 2005 Jun 07; 5(3):135-41. PubMed ID: 16127348
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun 07; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 20. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD.
    Gastroenterology; 1998 Jan 07; 114(1):15-22. PubMed ID: 9428213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.